Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07054606 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear
A Phase 4 study of Dry Eye, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 4
- Development phase
- 104
- Enrollment target
- 6
- Study locations
NCT07054606 is a Phase 4 study of Dry Eye that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 104 participants, above the 93-participant average among 41 other Dry Eye trials with a reported enrollment target (12% higher). The trial reports 6 study locations across 6 states.
The verdict
NCT07054606, a Phase 4 study of Dry Eye, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 104 participants
- Enrollment target
- 6
- Study locations
Study Summary
Assess the impact of concomitant Miebo use while wearing contact lenses
Conditions Studied
Interventions
- DRUG Perfluorohexyloctane ophthalmic solution
Study Locations (6)
California
- Site 101 - San Diego
Florida
- Site 107 - Longwood
Kansas
- Site 104 - Pittsburg
Minnesota
- Site 102 - Medina
New York
- Site 108 - Vestal
Ohio
- Site 103 - Athens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2025-07-02 |
| Est. Completion | 2025-11-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07054606
The ClinicalTrials.gov registry entry for NCT07054606 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 93-participant average among 41 other Dry Eye trials with a reported enrollment target (12% higher). The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye appearing as the primary indexed condition, and to 1 intervention - of which Perfluorohexyloctane ophthalmic solution is the first listed.
NCT07054606 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Kansas.
Frequently Asked Questions
What is clinical trial NCT07054606 about?
NCT07054606 is a clinical study titled "A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear". Assess the impact of concomitant Miebo use while wearing contact lenses
What is the current status of trial NCT07054606?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 104 participants. The study started on 2025-07-02. Estimated completion is 2025-11-03.
What conditions does trial NCT07054606 study?
This clinical trial studies the following conditions: Dry Eye.
What interventions are being tested in trial NCT07054606?
The interventions under investigation include: Perfluorohexyloctane ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT07054606?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07054606 being conducted?
This trial has 6 study locations across California, Florida, Kansas, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy of Kera Sol Tears on Signs and Symptoms of Surgical Temporary Ocular Discomfort Syndrome (STODS) in Subjects Following LASIK
RECRUITING · Phase 4
-
Quality of Life in Presbyopic Patients Who Are Treated With Qlosi
RECRUITING · Phase 4
-
Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work
RECRUITING · Phase 4
-
Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease
RECRUITING · Phase 4
-
Performance of Systane PRO Versus Refresh Optive Mega-3
RECRUITING · Phase 4
-
A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.